Editorial Mission

Editorial Principles

Every editorial decision at Sunny Pharma® is guided by six core principles. These principles govern what we cover, how we write it, who reviews it, and how we respond when information changes.

1. Purpose & Scope

This Editorial Policy governs all health, pharmaceutical, and clinical content published on sunnypharma.info. It applies to product information pages, condition guides, FAQ sections, news articles, blog posts, patient resources, and any other written or multimedia content accessible to the public.

This policy exists to:

• Ensure every piece of content is medically accurate and evidence-based
• Protect patients from misinformation about medications, dosing, and safety
• Build and maintain the trust of patients, caregivers, and healthcare providers
• Comply with applicable pharmaceutical advertising and health communication regulations in the United States and Canada
• Signal to search engines and third-party evaluators that Sunny Pharma® meets the highest standards of Experience, Expertise, Authoritativeness, and Trustworthiness (E-E-A-T)

2. Editorial Independence

Sunny Pharma®’s editorial content is produced independently and is not influenced by pharmaceutical manufacturers, distributors, or commercial partners. Sunny Pharma® does not sell medication or operate a pharmacy. Any discussion of medication pricing, access programs, or treatment options is provided strictly for informational and educational purposes.

If Sunny Pharma® participates in referral programs or affiliate partnerships, these relationships are disclosed in accordance with applicable consumer protection and advertising transparency standards. See Section 14: Funding & Commercial Transparency for full details.

2.1 Separation of Content and Commerce

Editorial content is created and reviewed by qualified medical and pharmaceutical professionals. No product manufacturer, supplier, or commercial partner may direct, alter, or withhold editorial content. Sponsored or partner content — if ever published — will be clearly and prominently labeled as such and held to the same medical accuracy standards as original editorial content.

2.2 No Editorial Conflicts of Interest

All contributors, reviewers, and editors are required to disclose any financial, professional, or personal relationships that could constitute a conflict of interest with respect to content they are authoring or reviewing. Undisclosed conflicts of interest are grounds for removal of content and disqualification from the editorial process.

3. Content Lifecycle

Every piece of content on sunnypharma.info follows a defined lifecycle from initial brief to eventual retirement or replacement. This ensures that nothing is published without review, and nothing remains live without periodic verification.

1. Topic Selection & Brief — The editorial team identifies content needs based on patient search intent, clinical relevance, and gaps in current coverage. Topics are approved before any writing begins.
2. Research & Drafting — A qualified health writer or pharmacist researcher drafts content using primary evidence sources: FDA-approved labeling, recognized clinical guidelines, and peer-reviewed literature.
3. Pharmaceutical Review — A licensed pharmacist reviews all drug-specific information including mechanism of action, dosing, drug interactions, contraindications, and storage.
4. Medical Editorial Review — A board-certified physician reviews the full article for clinical accuracy and appropriate context. Reviewer specialty is matched to the content area (see Section 6: Medical Review Board).
5. Editorial QA & Publication — A senior editor performs a final review for readability, compliance with this policy, citation formatting, and structured data accuracy before publishing.
6. Scheduled Review — Published content enters a review cycle. Drug pages are reviewed every 6 months; condition guides annually; pricing information quarterly (see Section 10: Content Updates & Corrections).
7. Update or Retirement — Content is updated in-line with a visible correction or review notice, or retired and redirected if superseded by newer, more complete content.

4. Content Creation Standards

4.1 Writing Standards

• Plain language at an accessible reading level (target: U.S. Grade 8–10), without sacrificing clinical accuracy
• Empathetic, non-stigmatizing language — particularly for HIV and Hepatitis C content, in alignment with UNAIDS and CDC communication guidelines
• Accurate use of brand names, generic names (INN), and drug class terminology
• Dosing information presented only in conjunction with a clear recommendation to consult a licensed prescriber
• No absolute or guaranteeing language regarding treatment outcomes (e.g., will cure, guaranteed results)
• Claims about medication cost or savings must be accurate, time-stamped, and regularly verified

5. Medical Review Process

All health, clinical, and pharmaceutical content published on sunnypharma.info undergoes a structured medical review process before publication, modeled on best practices established by leading health platforms including Healthline Media, WebMD, and Medscape.

5.1 Reviewer Credentials

Medical reviewers must hold current, valid licensure in their specialty jurisdiction. Accepted credentials include M.D. or D.O. with active board certification, Pharm.D. with clinical pharmacy practice experience, R.Ph. with relevant specialty experience, and N.P. or P.A. in an advisory or supporting review role. All credentials are verified prior to engagement and displayed on applicable content pages in accordance with Google’s E-E-A-T standards.

5.2 Reviewer Disclosure

Each piece of reviewed content displays a byline including the reviewer’s name, professional credentials, specialty, and the date of medical review. Reviewers must disclose any financial relationships with pharmaceutical manufacturers relevant to the content being reviewed.

6. Medical Review Board

6.1 Purpose

Sunny Pharma® maintains a Medical Review Board composed of licensed healthcare professionals and subject-matter experts who provide clinical oversight for health information published on sunnypharma.info. The Board ensures that educational content discussing medications, treatment guidelines, and disease management reflects current clinical evidence and accepted medical practice.

6.2 Areas of Expertise

Reviewers contributing to Sunny Pharma® content may include professionals with experience in infectious disease medicine and HIV treatment, antiretroviral therapy and HIV pharmacology, hepatology and Hepatitis C management, clinical pharmacy and pharmacology, and endocrinology and obesity medicine. Reviewers provide guidance only within their area of expertise.

6.3 Reviewer Credentials

Medical reviewers may hold credentials including Doctor of Medicine (M.D.) or Doctor of Osteopathic Medicine (D.O.), Doctor of Pharmacy (Pharm.D.), Registered Pharmacist (R.Ph.), or Nurse Practitioner (N.P.) or Physician Assistant (P.A.). All reviewers maintain current licensure in their respective jurisdictions, verified prior to engagement.

6.4 Role of Medical Reviewers

Medical reviewers provide editorial oversight and factual verification but do not provide patient-specific medical advice. Their role includes reviewing clinical claims for accuracy, verifying dosing and safety information against FDA-approved labeling, confirming alignment with major clinical guidelines, and recommending updates when new evidence becomes available.

6.5 Transparency on Content Pages

Where applicable, Sunny Pharma® content pages display the reviewer’s name, credentials, the date of medical review, and the most recent update date — so readers can assess the currency and authorship of information at a glance.

7. Content Categories & Specific Standards

7.1 HIV Treatment Content

Content covering HIV antiretroviral therapy — including medications such as Biktarvy, Descovy, Tivicay, Triumeq, Truvada, Reyataz, and Prezista — must accurately represent indication (treatment vs. PrEP) without conflating the two, reference current DHHS Adult and Adolescent ARV Treatment Guidelines, use person-first destigmatizing language consistent with CDC and UNAIDS recommendations, clearly note the requirement for a valid prescription and ongoing clinical monitoring, and not make therapeutic equivalence claims between branded and generic formulations without regulatory citation.

7.2 Hepatitis C Treatment Content

Hepatitis C treatment content must reference current AASLD/IDSA HCV Guidance as the authoritative clinical standard, correctly distinguish between genotype-specific and pangenotypic regimens, and accurately represent cure rates (SVR12) from clinical trial data only — no extrapolation without citation.

7.3 Weight Loss Medication Content

Content covering weight management medications must comply with FTC guidelines on health claims, accurately represent FDA-approved indications and contraindications, not imply results beyond those demonstrated in controlled clinical trials, and always include a recommendation to consult a physician before initiating treatment.

7.4 Pricing & Cost Information

All pricing information must be clearly dated, accompanied by a disclaimer that prices are subject to change, and verified for accuracy on a minimum quarterly basis. Comparative pricing claims must use current, verifiable reference prices.

8. Sourcing & Citation Standards

All factual and clinical claims in published content must be supported by in-text citations linked to primary or secondary sources. Citations must link directly to the source document (PubMed abstract, FDA label page, official guideline PDF). Sources must be dated within the last five years for clinical content, unless referencing foundational pharmacology data. Secondary aggregators are not permitted as sole sources for clinical claims. A minimum of three credible sources is required for any standalone clinical article. Patient-facing content cites sources in an accessible format with links; clinical-facing content follows AMA citation style.

9. Evidence Standards & Medical Sources

Sunny Pharma® applies a strict evidence hierarchy to every clinical claim. The hierarchy below defines which sources are authoritative for drug information, treatment guidance, and outcome data published on this platform.

9.1 Guideline Currency

Clinical guidelines are updated regularly by their issuing bodies. Sunny Pharma® monitors for guideline updates in its key therapeutic areas and initiates content review within 30 days of a significant guideline change. The specific guidelines governing each therapeutic area are:

• HIV treatment: DHHS Adult and Adolescent ARV Treatment Guidelines (updated continuously)
• Hepatitis C treatment: AASLD/IDSA HCV Guidance (updated continuously)
• Weight management: Endocrine Society Clinical Practice Guidelines; American Gastroenterological Association guidance on GLP-1 medications

9.2 FDA Label Changes

When the FDA approves a label change for any drug covered on sunnypharma.info — including new indications, black box warning updates, new contraindications, or revised dosing — the relevant content is flagged for immediate review, updated within 14 days, and the update is recorded in our Content Audit Log with a visible correction notice on the affected page.

10. Content Updates, Corrections & Retractions

Medical information evolves. Sunny Pharma® is committed to keeping content current and correcting errors promptly and transparently.

10.1 Regular Content Reviews

10.2 Corrections Policy

If factual errors are identified in published content — whether discovered internally or reported by readers — Sunny Pharma® will: (1) investigate within 48 hours, (2) publish a transparent correction notice at the top of the affected page, (3) update all relevant citations, and (4) document the correction in our internal Content Audit Log. We do not silently edit content to conceal errors. Readers are encouraged to report inaccuracies via our Contact page.

10.3 Content Dating & Transparency

Every piece of health and clinical content on sunnypharma.info displays three dates: (1) original publication date, (2) medical review date, and (3) last updated date — allowing readers and search evaluators to assess the currency of information at a glance.

11. Legal & Regulatory Compliance

Sunny Pharma® is an independent educational platform and all content is designed to comply with applicable regulations in both the United States and Canada. Sunny Pharma® does not sell medication, dispense prescriptions, or operate a pharmacy.

• Content does not constitute medical advice, diagnosis, or treatment. Every clinical page includes a standardized disclaimer directing patients to consult their prescribing physician or pharmacist
• Prescription drug information conforms to FDA-approved labeling. Off-label use information, where published, is clearly identified as such and supported by peer-reviewed evidence
• Pharmaceutical advertising content (if any) complies with FDA regulations for direct-to-consumer drug advertising (21 CFR Part 202) and Health Canada’s equivalent standards
• Content pertaining to PrEP medications (e.g., Truvada, Descovy) complies with CDC communication standards and avoids stigmatizing language
• All patient privacy considerations are addressed under our Privacy Policy in accordance with HIPAA and PIPEDA

12. Audience Considerations

Sunny Pharma® content serves a dual audience: patients and caregivers seeking medication information, and healthcare providers seeking clinical reference material. Content is clearly differentiated by audience where applicable.

• Patient-facing content uses accessible language and focuses on real-world utility: cost, access, side effect management, and adherence
• Clinical reference content uses appropriate medical terminology and links directly to primary literature
• All content maintains sensitivity to the unique emotional and social dimensions of HIV, Hepatitis C, and weight management — conditions often accompanied by stigma, anxiety, and complex socioeconomic factors

13. SEO & Content Integrity

Sunny Pharma® achieves search visibility through the merit of content quality — not manipulation. Our SEO practices fully align with Google’s Search Essentials and the principles of Helpful Content.

• Content is written for patients and healthcare consumers first — not search engines
• We do not engage in keyword stuffing, cloaking, hidden text, or any other deceptive SEO practice
• All structured data (schema markup) accurately reflects page content and follows Schema.org standards for MedicalWebPage, Drug, and FAQPage types
• Internal linking is editorially relevant and serves the reader’s informational journey
• We actively seek to earn backlinks from authoritative health and medical institutions through content merit
• Content length and structure are determined by the informational needs of the reader, not arbitrary keyword density targets

14. Funding & Commercial Transparency

Sunny Pharma® is committed to transparency regarding how the platform is funded and how commercial relationships are managed.

14.1 Independent Editorial Content

All editorial content on sunnypharma.info is created independently. Commercial relationships do not influence the selection of topics covered, the accuracy of clinical information presented, the conclusions reached in educational content, or the inclusion or exclusion of specific medications. Editorial decisions are made solely by the Sunny Pharma® editorial team.

14.2 Referral and Affiliate Relationships

Sunny Pharma® may participate in referral or affiliate programs with third-party services related to medication access or healthcare resources. Where such relationships exist, they will be clearly disclosed on the relevant pages, will not affect the clinical accuracy of the content, and readers will never be required to use a third-party service. Sunny Pharma® does not sell or dispense medications.

14.3 No Pharmaceutical Manufacturer Sponsorship

Sunny Pharma® does not accept payment from pharmaceutical manufacturers in exchange for editorial coverage, favorable product descriptions, or preferential placement within educational content. Medication information is based exclusively on FDA-approved prescribing information, recognized clinical guidelines, and peer-reviewed medical research.

14.4 Advertising and Sponsored Content

If advertising or sponsored content is ever displayed on sunnypharma.info, it will be clearly labeled as “Advertisement” or “Sponsored Content,” visually distinct from editorial material, and will not be presented as medical advice or an editorial recommendation. Sponsored material must still comply with the accuracy and safety standards described in this policy.

14.5 Commitment to Reader Trust

Sunny Pharma® believes that transparent disclosure of funding sources and commercial relationships is essential to maintaining reader trust. Our goal is to ensure that readers can always clearly distinguish between educational editorial content, commercial relationships, and advertising or promotional material.

15. Policy Governance & Review

This Editorial Policy is owned by the Sunny Pharma® Editorial Director and reviewed annually, or sooner in the event of significant regulatory changes, search engine algorithm updates with editorial implications, or substantive changes to the clinical guidelines governing our key therapeutic areas.

All staff, contractors, and third-party contributors involved in content creation or review for sunnypharma.info must acknowledge and agree to this policy prior to engagement. Questions regarding this policy should be directed to the editorial team via the Contact page.